Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

 
• By Mandy Jackson
A Businessperson Stopping Colorful Dominoes From Falling On Desk
Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy

More from Clinical Trials

More from R&D